Evotec Initiates “Priority Reset” Cutting 400 Roles
In a blunt assessment of the German biotech’s situation after reporting earnings for the first half of the year, CEO Christian Wojczewski, Ph.D., said revenues and profitability for the six-month period “have been more challenging for the company than expected.”
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced progress within the Company's strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes. Evotec receives a US$ 25 m payment to progress further research
Evotec SE Reports First Half-year 2024 Results on 14 August 2024
65LAB and Duke-NUS award US$1.85 million to combat chronic inflammation
Evotec SE, a life science company, announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer. Under the agreement, Evotec and Pfizer will initially focus on early discovery research for metabolic and infectious diseases.
Evotec SE has entered into a multi-year master research collaboration and option and license agreement with Pfizer under which the companies will focus on early discovery research for metabolic and infectious diseases.
HAMBURG, GERMANY / ACCESSWIRE / July 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(NASDAQ:EVO) (MDAX/TecDAX , ISIN: DE0005664809) today announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer. Under the agreement, Evotec and Pfizer will initially focus on early discovery research for metabolic and infectious diseases.
Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz
Tubulis` TUB-040 Gets FDA Fast Track For Ovarian Cancer